International Clinical Trial: The efficacy and safety of Obinutuzumab ß in the treatment of primary membranous nephropathy: A prospective, open-label, single-center study

Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134998) titled 'The efficacy and safety of Obinutuzumab ß in the treatment of primary membranous nephropathy: A prospective, open-label, single-center study' on Oct. 22.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Yantai Yuhuangding Hospital

Condition: Primary Membranous Nephropathy

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-10-23

Target Sample Size: treatment group:36;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=348942

Disclaimer: Curated by HT Syndication....